
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics presents a positive growth outlook, supported by management's guidance predicting significant revenue increases from Aucatzyl, with projections of $120M-135M for 2026, indicating a 60-80% year-over-year growth as the network expands. The substantial rise in CAR-T utilization in the UK, anticipated to be three times that of the US, is expected to further bolster the company's revenue potential by 2026. Additionally, the success of Blincyto in expanding its label and usage suggests a favorable market environment for Autolus’s programs, enhancing the appeal of its pipeline therapies.
Bears say
Autolus Therapeutics PLC has experienced a significant decline in its stock price, dropping approximately 48% since July 2025, in stark contrast to a 40% increase in the NASDAQ Biotechnology Index, which raises concerns about the company’s flat quarter-over-quarter revenue growth in B-ALL. The company's recent product Aucatzyl launched in the first quarter of 2025, but sales remained stagnant for the subsequent quarters, primarily due to limitations in manufacturing capacity and enrollment gaps that hindered product infusion readiness. Additional risks, including potential safety signals, insufficient efficacy in clinical trials, greater-than-expected competition, and financial concerns such as the anticipated need for $1.0 billion in capital through 2038, contribute to a negative outlook for Autolus Therapeutics's stock.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares